ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
44 announcements with these filters
Dr Reddys Laboratories Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing details holdings of promoters, institutions, and public shareholders.
Management discloses a significant manufacturing setback for Semaglutide injection due to out-of-specification impurity levels during scale-up, causing a temporary multi-month supply halt.
Dr. Reddy’s Laboratories disclosed that certain semaglutide batches are out of specification, causing a delay in commercial supplies. The company is investigating the issue.
Dr. Reddy's sent letters to shareholders providing a link to the FY 2025-26 Integrated Annual Report. The notice includes details for the 42nd AGM.
Dr. Reddy's Laboratories notified the 42nd AGM on July 23, 2026. The meeting will be held via video conferencing.
Dr. Reddy's Laboratories has submitted its Integrated Annual Report for FY 2025-26. The report includes corporate overviews, strategic reviews, and statutory reports.
USFDA completed a pre-license inspection at Dr Reddy's Bachupally facility. The company received a Form 483 with seven observations.
Dr. Reddy's launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the U.S. This first-to-market launch strengthens its oncology portfolio and patient access.
Dr. Reddy's Laboratories allotted 12,100 equity shares under its Employee Stock Option Schemes. The allotment increases the company's total paid-up share capital.
Dr. Reddy's Laboratories allotted 12,100 equity shares following the exercise of employee stock options. The shares rank pari-passu with existing equity, slightly increasing the total paid-up capital.
Dr. Reddy's Laboratories filed its FY2026 Annual Report in Form 20-F with the US SEC. The report contains consolidated financial statements prepared under IFRS standards.
Dr. Reddy's Laboratories submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The independent report confirms regulatory compliance with no significant deviations.
Dr. Reddy's senior management will ring the NYSE Closing Bell on May 29, 2026. The ceremony celebrates the company's 25th anniversary of listing on the exchange.
Dr. Reddy's Laboratories launched its generic Semaglutide Injection in Canada following Health Canada approval. This marks the first generic Semaglutide authorization in a G7 country.